Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?

Keywords

Pioglitazone, Rosiglitazone, Medicine, Internal medicine, Endocrinology

References

• Pioglitazone and Rosiglitazone Have Different Effects on Serum Lipoprotein Particle Concentrations and Sizes in Patients With Type 2 Diabetes and DyslipidemiaMark A. Deeg, John B. Buse, Ronald Goldberg — 2007
• Effects of Pioglitazone on Endothelial Function, Insulin Sensitivity, and Glucose Control in Subjects With Coronary Artery Disease and New-Onset Type 2 DiabetesHarald Sourij, Robert Zweiker, Thomas C. Wascher — 2006
• Rosiglitazone Monotherapy Is Effective in Patients with Type 2 DiabetesHarold E. Lebovitz — 2001
• Effects of Pioglitazone on Endothelial Function, Insulin Sensitivity, and Glucose Control in Subjects With Coronary Artery Disease and New-Onset Type 2 DiabetesHarald Sourij — 2006
• Rosiglitazone Monotherapy Is Effective in Patients with Type 2 DiabetesHarold E. Lebovitz, Jo Dole, Rita Patwardhan — 2001
• White blood cell count and cardiovascular disease. Insights from the Framingham StudyWilliam B. Kannel — 1992

Cited by

• Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureasMaya Jacob — 2010
• Dapagliflozin – do we need it registered for type 2 diabetes?Sheila A Doggrell, Rinku A. Tuli — 2014
• Rosiglitazone via PPARγ-dependent suppression of oxidative stress attenuates endothelial dysfunction in rats fed homocysteine thiolactoneXu-Hong YANG, Peng Li, Yaling Yin — 2015
• The Effects of Thiazolidinediones on Metabolic Complications and Lipodystrophy in HIV-Infected PatientsJussi Sutinen — 2008
• Factors affecting proteoglycan synthesis and structure that modify the interaction with lipoproteinsSundy N.Y. Yang, Narin Osman, Micah L. Burch — 2009
• Optimized mixture of hops rho iso-alpha acids-rich extract and acacia proanthocyanidins-rich extract reduces insulin resistance in 3T3-L1 adipocytes and improves glucose and insulin control in db/db miceMatthew L. Tripp, Gary Darland, Veera Reddy Konda — 2012
• Effect of Pioglitazone, Quercetin, and Hydroxy Citric Acid on the Lipid Profile and Lipoproteins in Experimentally Induced Non-alcoholic Steatohepatitis (NASH)Surapaneni Krishna Mohan, Mallika Jainu — 2014
• Pioglitazone: a valuable component of combination therapy for type 2 diabetes mellitusΝικόλαος Παπάνας, Niki Katsiki, Apostolos Hatzitolios — 2011
• Transient Increase in HDL‐Cholesterol During Weight Gain by Hyperalimentation in Healthy SubjectsTorbjörn Lindström, Stergios Kechagias, Martin Carlsson — 2011
• SR2067 Reveals a Unique Kinetic and Structural Signature for PPARγ Partial AgonismLaura M. van Marrewijk, Steven W. Polyak, Marcel Hijnen — 2015
• Comment and response to: dapagliflozin – do we need it registered for type 2 diabetes?Serge Jabbour — 2014
• Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritisMichael J. Kraakman, Dragana Dragoljevic, Hélène L. Kammoun — 2016
• Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 DiabetesMaryam Khavandi, Francisco Duarte-Martínez, Henry N. Ginsberg — 2017
• Investigations on Binding Pattern of Kinase Inhibitors with PPARγ: Molecular Docking, Molecular Dynamic Simulations, and Free Energy Calculation StudiesMohit Mazumder, Prija Ponnan, Umashankar Das — 2017
• Pioglitazone/metformin adduct regulates insulin secretion and inhibits high glucose‐induced apoptosis via p21‐p53‐MDM2 signaling in INS‐1 cellsRongxing Liu, Yan Ma, Xuelian Hu — 2018
• Efficacy and Safety of Pioglitazone/Metformin Fixed-Dose Combination Versus Uptitrated Metformin in Patients with Type 2 Diabetes without Adequate Glycemic Control: A Randomized Clinical TrialLixin Guo, L. S. Wang, D. Tian — 2024
• Red clover extractMonika Mueller, Alois Jungbauer — 2008

Related papers

• The comparison study of pioglitazone and rosiglitazone on type 2 diabetes with hyperlipemiaXU Xiang-ji — 2009
• Cardiovascular safety of rosiglitazone and pioglitazoneYu Lu, Delin Ma — 2015
• Rosiglitazone and Pioglitazone for the Treatment of Alzheimer's DiseaseBenjamin Miller, Kristine C. Willett, Alicia R Desilets — 2011
• The impacts of thiazolidinediones on circulating C-reactive protein levels in different diseases: a meta-analysis.Yulan Zhao, Xuelian He, Chengjin Huang — 2010
• Pioglitazone Exhibits a Beneficial Effect on CIMT in Patients with Type 2 DiabetesT. O'Loughlin, T Mazzone — 2006
• Pharmacokinetic Interactions with ThiazolidinedionesAndr J Scheen — 2007
• Chemical Proteomics‐Based Analysis of Off‐target Binding Profiles for Rosiglitazone and Pioglitazone: Clues for Assessing Potential of CardiotoxicityBrian Hoffmann, Mohamed El Mansy, Daniel S. Sem — 2012
• An observational study of the effect of two thiazolidinediones on blood lipid levels: Rosiglitazone and pioglitazone in routine clinical practice.Deborah Griffis, Trentnt McLaughlin, Riad Dirani — 2004
• Pioglitazone vs. Glimepiride in Type 2 DiabetesJoel M. Gore — 2006